What neoadjuvant approach do you recommend for a cisplatin-eligible patient with cT2N0 muscle-invasive bladder cancer given KEYNOTE-B15's findings?
Does the EV plus pembrolizumab data change what you offer? Does variant histology or hydronephrosis change that?
Galsky et al. PMID: 42485627